Clozapine N-oxide

315,00 €

Zzgl. MwSt.

ArtNr	HY-17366-50mg
Hersteller	MedChem Express
CAS-Nr.	34233-69-7
Menge	50mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Brain Cancer Nervous System Cancer
Typ	Inhibitors
Purity	99.98
Citations	Acta Pharmacol Sin. 2023 Jan 25. Acta Physiol. 2023 Jan 4;e13917. Adv Sci (Weinh). 2023 Apr 14;e2204824. Adv Sci (Weinh). 2023 Jun 16;e2301110. Anesthesiology. 2021 Jul 13. Anesthesiology. 2021 Jul 16. Biol Psychiatry. 2017 May 1;81(9):737-747. bioRxiv. 2023 Oct 9. Brain Behav Immun. 2023 Jun 5;S0889-1591(23)00141-1. Brain Commun. 30 August 2022. Brain Stimul. 2023 Dec 23;17(1):49-64. Cell Metab. 2022 Feb 1;34(2):285-298.e7. Cell Rep. 2021 Mar 23;34(12):108889. Cell Rep. 2023 Dec 3;42(12):113551. Cell Rep. 2023 Mar 21;42(4):112290. CNS Neurosci Ther. 2022 Nov 15. CNS Neurosci Ther. 2023 Dec 17. Commun Biol. 2021 Sep 16;4(1):1088. Commun Biol. 2023 Jan 14;6(1):50. Ecotoxicol Environ Saf. 2023 Jun 29;262:115205. Elife. 2021 Sep 16;10:e67535. FASEB J. 2020 Sep;34(9):11913-11924. Front Cell Neurosci. 2021 Apr 30;15:671473. Front Neurosci. 2020 Jul 14;14:646. iScience. 2023 Aug 14. iScience. 2023 Oct 20. J Neuroinflammation. 2022 Jun 27;19(1):166. J Neuroinflammation. 2022 May 27;19(1):123. J Neuropathol Exp Neurol. 2023 Jul 21;nlad056. J Neurosci. 2021 Oct 11;JN-RM-0881-21. Life Metabolism. 2023 Feb 4. Life Sci. 2020 Oct 1;258:118099. Nat Commun. 2020 Jun 5;11(1):2847. Nat Commun. 2020 Nov 27;11(1):6045. Nat Commun. 2022 Apr 25;13(1):2233. Nat Commun. 2023 Apr 17;14(1):2182. Nat Neurosci. 2022 Nov 17. Nat Neurosci. 2023 Apr;26(4):542-554. Neural Regen Res. 2024 Feb;19(2):425-433. Neurobiol Dis. 2023 May 12;106155. Neurobiol Stress. 22 September 2022, 100492. Neuropharmacology. 2018 Jun;135:474-486. Neuropsychopharmacology. 2022 Dec 16. Neuropsychopharmacology. 2024 Jan 5. Neurosci Bull. 2021 Jun 18. Neurosci Bull. 2021 May;37(5):597-610. Neurosci Bull. 2022 Nov 7. Neurosci Bull. 2023 Jan 11. Neuroscience. 2019 Aug 21;414:299-310. P Natl Acad Sci USA. 13, 2021 118 (28) e2103505118. Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16583-16592. Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2215590120. Prog Neuropsychopharmacol Biol Psychiatry. 18 December 2021, 110496. Psychoneuroendocrinology. 2020 Jul;117:104690. Research Square Preprint. 2021 Mar. Research Square Preprint. 2023 Sep 22. Research Square Print. September 6th, 2022 SSRN. 2023 Jul 18. Theranostics. 2023 May 11;13(9):2946-2961. Theranostics. 2024 Jan 1;14(2):480-495. Transl Psychiatry. 2020 Jun 20;10(1):202. University of Michigan, Horace H. Rackham School of Graduate Studies. 2018 Oct. Cells. 2022 Dec 21;12(1):26. Cells. 2023, 12(1), 26. iScience. 2022: 105840. Pharmacol Res. 2023 Apr 15;106773. [1]Wess J, et al. Novel designer receptors to probe GPCR signaling and physiology. Trends Pharmacol Sci. 2013 Jul;34(7):385-92. [2]Silva RR, et al. Evaluation of Functional Selectivity of NSC 170973, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Front Pharmacol. 2019 Jun 4;10:628. [3]Zorn SH, et al. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994 Nov 15;269(3):R1-2. [4]Manvich DF, et al. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep. 2018 Mar 1;8(1):3840. [5]van der Peet PL, et al. Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs. MethodsX. 2018 Mar 23;5:257-267. [6]Joseph Cichon, et al. Branch-specific dendritic Ca(2+) spikes cause persistent synaptic plasticity. Nature. 2015 Apr 9;520(7546):180-5.
Smiles	[O-][N+]1(C)CCN(C2=NC3=CC(Cl)=CC=C3NC4=CC=CC=C42)CC1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	34233-69-7
Lieferbar
Product Description	Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide can cross the blood-brain barrier[1][2][3][4]. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist[5][6].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neuromodulation
Molecular Weight	342.82
Clinical Information	No Development Reported
Solubility	DMSO : 100 mg/mL (ultrasonic)\|H2O : 1 mg/mL (ultrasonic)
Isoform	mAChR3; mAChR4
Pathway	GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-17366-50mg-safety-datasheet.pdf